ARIAD to Webcast Conference Call on Third Quarter 2007 Financial Results.CAMBRIDGE, Mass. -- ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARIA) will hold a live webcast of its quarterly conference call at 8:30 a.m. (EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) on Wednesday, November 7, 2007. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior management will discuss the Company's financial results as of September 30, 2007, progress towards 2007 goals, and additional corporate activities. The Company will announce the highlights of these topics in a press release to be issued before the market opens on November 7, 2007 prior to the conference call. The live webcast can be accessed by visiting the investor relations Investor relations The process by which the corporation communicates with its investors. section of the Company's website at http://www.ariad.com/investor. The call can be accessed by dialing 1-800-591-6923 (domestic) or 617-614-4907 (international) five minutes prior to the start time and providing the passcode 30619185. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for two weeks. About ARIAD ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling Cell signaling is part of a complex system of communication that governs basic cellular activities and coordinates cell actions. The ability of cells to perceive and correctly respond to their microenvironment is the basis of development, tissue repair, and immunity as well as with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate. Medinol Ltd. and ICON Medical Corp. are also developing deforolimus-eluting stents to prevent restenosis of injured in·jure tr.v. in·jured, in·jur·ing, in·jures 1. To cause physical harm to; hurt. 2. To cause damage to; impair. 3. vessels following interventions in which stents are used in conjunction with balloon angioplasty balloon angioplasty: see under angioplasty. . ARIAD has an exclusive license to pioneering technology and patents related to certain NF-kB treatment methods, and the discovery and development of drugs to regulate NF-kB cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion